Evaluation of bioequivalence of two enrofloxacin formulations after intramuscular administration in goats

다국어 초록 (Multilingual Abstract)

The present study was planned to evaluate the bioequivalence of two commercial formulations of enrofloxacin, which have been marketed as 10% injectable solution after intramuscular administration at a single dose of 2.5 mg/kg body weight to 12 clinically healthy goats The study was carried out on the basis of crossover design. The two formulations were: Baytril as a reference product and Spectrama Vet as a test product. The plasma concentrations of enrofloxacin were measured by high performance liquid chromatography (HPLC) with UV detector. The pharmacokinetics of that data was performed using non-compartmental analysis. The maximum plasma concentration ($C_{max}$), time to reach peak concentration ($T_{max}$), area under concentration-time curve (AUC), elimination half-life ($t_{0.5el}$) were 1.14 and $1.05{\mu}g/mL$, 0.79 and 0.83 h, 5.70 and $5.79{\mu}g.h/mL$, 5.19 and 5.39 h for Baytril and Spectrama Vet, respectively. The 90% confidence interval for the mean ratio of $T_{max}$, $C_{max}$ and AUC were 94.72-116.2, 87.88-97.16 and 86.44-118.72%, respectively. These values falls within the European Medicines Agency bioequivalence acceptance range of 80-125% for both $T_{max}$ and AUC and between 75-133% for $C_{max}$. In conclusion, Spectrama-Vet is bioequivalent to Baytril and both products can be used as interchangeable drug in veterinary medicine practice.

참고문헌 (Reference)

1 Toutain PL, "Veterinary drug bioequivalence determination" 20 : 79-90, 1997

2 Madaras-Kelly KJ, "Twenty-four-hour area under the concentration-time curve/ MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model" 40 : 627-632, 1996

3 Walker RD, "The use of fluoroquinolones for companion animal antimicrobial therapy" 78 : 84-90, 2000

4 Vancutsem PM, "The fluoroquinolone antimicrobials: structure, antimicrobial activity, pharmacokinetics, clinical use in domestic animals and toxicity" 80 : 173-186, 1990

5 Alvinerie M, "Some pharmacokinetic parameters of eprinomectin in goats following pour-on administration" 23 : 449-455, 1999

6 Zechiedrich EL, "Roles of topoisomerase IV and DNA gyrase in DNA unlinking during replication in Escherichia coli" 9 : 2859-2869, 1995

7 Lewbart G, "Pharmacokinetics of enrofloxacin in the red pacu (Colossoma brechypomum) after intramuscular, oral and bath administration" 20 : 124-128, 1997

8 Kaartinen L, "Pharmacokinetics of enrofloxacin in new-born and oneweek- old calves" 20 : 479-482, 1997

9 Haritova A, "Pharmacokinetics of enrofloxacin in lactating sheep" 74 : 241-245, 2003

10 Ahangar AH, "Pharmacokinetics of enrofloxacin in febrile crossbred bovine calves" 32 : 305-308, 2000

11 Giguere S, "Pharmacokinetics of enrofloxacin in adult horses and concentration of the drug in serum, body fluids and endometrial tissues after repeated intragastrically administered doses" 57 : 1025-1030, 1996

12 Kim MS, "Pharmacokinetics of enrofloxacin in Korean catfish (Silurus asotus)" 29 : 397-402, 2006

13 Elmas M, "Pharmacokinetics of enrofloxacin following intravenous and intramuscular administration in Angora rabbits" 82 : 242-245, 2007

14 Rao GS, "Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid" 163 : 85-93, 2002

15 Kung K, "Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and oral administration of Baytril in dogs" 16 : 462-468, 1993

16 Rao GS, "Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intramuscular administration of enrofloxacin in goats" 25 : 197-204, 2001

17 Kaartinen L, "Pharmacokinetics of enrofloxacin after single intravenous, intramuscular and subcutaneous injections in lactating cows" 18 : 357-362, 1995

18 Elmas M, "Pharmacokinetics of enrofloxacin after intravenous and intramuscular administration in Angora goats" 65 : 64-67, 2001

19 Davis JL, "Pharmacokinetics and tissue distribution of enrofloxacin and its active metabolite ciprofloxacin in calves" 30 : 564-571, 2007

20 Anadon A, "Pharmacokinetic variables and tissue residues of enrofloxcin and ciprofloxacin in healthy pigs" 60 : 1377-1382, 1999

21 Broome RL, "Pharmacokinetic properties of enrofloxacin in rabbits" 52 : 1835-1841, 1991

22 Walker RD, "Pharmacokinetic evaluation of enrofloxacin administered orally to healthy dogs" 53 : 2315-2319, 1992

23 Forrest A, "Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients" 37 : 1073-1081, 1993

24 Lode H, "Pharmacodynamics of fluoroquinolones" 27 : 33-39, 1998

25 Drusano GL, "Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis" 37 : 483-490, 1993

26 Dudley MN, "Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones" 91 : 45S-50S, 1991

27 Bimazubute M, "Penetration of enrofloxacin into the nasal secretions and relationship between nasal secretions and plasma enrofloxacin concentrations after intramuscular administration in healthy pigs" 33 : 183-188, 2010

28 Gibaldi M, "Non Compartmental Analysis Based on Statistical Moment Theory Pharmacokinetics" Marcel Dekker 409-417, 1982

29 Abo El-Sooud K, "Influence of albendazole on the disposition kinetics and milk antimicrobial equivalent activity of enrofloxacin in lactating goats" 48 : 389-395, 2003

30 Prescott JF, "In vitro susceptibility of selected veterinary bacterial pathogens to ciprofloxacin, enrofloxacin and norfloxacin" 54 : 195-197, 1990

31 Brown SA, "Fluoroquinolones in animal health" 19 : 1-14, 1996

32 Schroder J., "Enrofloxacin: a new antimicrobial agent" 60 : 122-124, 1989

33 Dorfman M, "Enrofloxacin concentrations in dogs with normal prostate and dogs with chronic bacterial prostatitis" 56 : 386-390, 1995

34 Langston VC, "Disposition of single dose oral enrofloxacin in the horse" 19 : 316-319, 1996

35 Elsheikh HA, "Disposition kinetics of enrofloxacin (Baytril 5%) in sheep and goats following intravenous and intramuscular injection using a microbiological assay" 73 : 125-129, 2002

36 Ovando HG, "Comparative pharmacokinetics of enrofloxacin and ciprofloxacin in chickens" 22 : 209-212, 1999

37 Haddad NS, "Combined pharmacokinetics of gentamicin in pony mares after a single intravenous and intramuscular administration" 46 : 2004-2007, 1985

38 Ozdemir N, "Bioequivalence study of twolong-acting oxytetracycline formulations in sheep" 30 : 929-934, 2006

39 Nielsen P, "Bioavailability of enrofloxacin after oral administration to fed and fasted pigs" 80 : 246-250, 1997

40 Chen ML, "Bioavailability and bioequivalence: an FDA regulatory overview" 18 : 1645-1650, 2001